You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

505 Results
Document
Aug 2025
Document
Aug 2025
Document
Aug 2025
Document
Aug 2025
Document
Aug 2025
Document
Aug 2025
Document
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Exceptional Access Program
    Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ivosidenib,
azaCITIDine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Guidelines and Advice
Status: Current
ID: GL END 4-19
Updated
Nov 2025
Document
New
Nov 2025
Document
New
Nov 2025

Pages